Finally, EZH2 activity in cancer is modulated by various oncogenic mutations in EZH2 (Tiffen et al., 2015b; Zingg et al., 2015; Souroullas et al., 2016) and post-translational modifications of components of the PRC2 complex (Li et al., 2020; Yang and Li, 2020), which might influence the output of EZH2-targeted therapies. The gene discussed is EZH2; the disease is cancer.